These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20859636)

  • 21. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder.
    Wade A; Gembert K; Florea I
    Curr Med Res Opin; 2007 Jul; 23(7):1605-14. PubMed ID: 17559755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
    Demyttenaere K; Andersen HF; Reines EH
    Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P; Andersen HF; Wade A
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors predicting relapse in elderly patients with major depressive disorder treated with escitalopram in an outpatient setting.
    Dolberg O; Larsson Lönn S; Kvist K
    Curr Med Res Opin; 2014 Jul; 30(7):1301-7. PubMed ID: 24628498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of escitalopram compared to citalopram: a meta-analysis.
    Montgomery S; Hansen T; Kasper S
    Int J Neuropsychopharmacol; 2011 Mar; 14(2):261-8. PubMed ID: 20875220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
    Nelson JC
    Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database.
    Baldwin DS; Stein DJ; Dolberg OT; Bandelow B
    Hum Psychopharmacol; 2009 Jun; 24(4):269-75. PubMed ID: 19334042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder.
    Saghafi R; Brown C; Butters MA; Cyranowski J; Dew MA; Frank E; Gildengers A; Karp JF; Lenze EJ; Lotrich F; Martire L; Mazumdar S; Miller MD; Mulsant BH; Weber E; Whyte E; Morse J; Stack J; Houck PR; Bensasi S; Reynolds CF
    Int J Geriatr Psychiatry; 2007 Nov; 22(11):1141-6. PubMed ID: 17486678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized, Double-Blind, Placebo-Controlled Trial of Escitalopram in Patients with Asthma and Major Depressive Disorder.
    Brown ES; Sayed N; Van Enkevort E; Kulikova A; Nakamura A; Khan DA; Ivleva EI; Sunderajan P; Bender BG; Holmes T
    J Allergy Clin Immunol Pract; 2018; 6(5):1604-1612. PubMed ID: 29409976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of escitalopram on sleep problems in depressed patients.
    Lader M; Andersen HF; Baekdal T
    Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.
    Uher R; Tansey KE; Dew T; Maier W; Mors O; Hauser J; Dernovsek MZ; Henigsberg N; Souery D; Farmer A; McGuffin P
    Am J Psychiatry; 2014 Dec; 171(12):1278-86. PubMed ID: 25017001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
    Llorca PM; Azorin JM; Despiegel N; Verpillat P
    Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
    Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R;
    J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder.
    Dreimüller N; Wagner S; Engel A; Braus DF; Roll SC; Elsner S; Tadić A; Lieb K
    BMC Psychiatry; 2019 Jan; 19(1):24. PubMed ID: 30642308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Escitalopram but not placebo modulates brain rhythmic oscillatory activity in the first week of treatment of Major Depressive Disorder.
    Leuchter AF; Hunter AM; Jain FA; Tartter M; Crump C; Cook IA
    J Psychiatr Res; 2017 Jan; 84():174-183. PubMed ID: 27770740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heart rate variability as a biomarker of anxious depression response to antidepressant medication.
    Kircanski K; Williams LM; Gotlib IH
    Depress Anxiety; 2019 Jan; 36(1):63-71. PubMed ID: 30311742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model.
    Montgomery SA; Loft H; Sánchez C; Reines EH; Papp M
    Pharmacol Toxicol; 2001 May; 88(5):282-6. PubMed ID: 11393591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.